A New Strategy for Controlled In Situ Release of IL‐2 from Tumor Spheroids Using a NIR‐II Light‐Mediated Optogenetic Manipulation System
Advanced Materials · 2026
DOI: 10.1002/adma.202516726 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Hongrui Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Beijing National Laboratory for Molecular Sciences, Key Laboratory of Organic Solids, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 1…. Hauptthemen laut MEDLINE: Interleukin-2, Spheroids, Cellular, Optogenetics, Infrared Rays. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Interleukin‐2 (IL‐2) is a clinically significant immunotherapeutic agent; its short half‐life and poor targeting specificity in vivo have made controlled in situ release an important area of investigation. However, traditional 2D cell experiments and animal studies cannot fully replicate the real environment of human tumors and are limited by interspecies heterogeneity. Here, a NIR‐II light‐mediated optogenetic manipulation system based on photothermal conjugated polymer nanoparticles is successfully constructed, enabling the controlled in situ release of IL‐2 from 3D tumor spheroids. Maintaining tumor spheroids at a relatively low temperature (≈40 °C) can enhance IL‐2 release by up to 4.3 times upon irradiation with 1080 nm laser for 30 min. The released IL‐2 further activates peripheral NK‐92 cells, enhancing the efficacy of immunotherapy. Additionally, the in situ release of IL‐2 specifically upregulates the expression of IL‐2RA on NK‐92 cells, facilitating the formation of high‐affinity complexes between IL‐2 and IL‐2RA. This process activates multiple signaling pathways, including JAK‐STAT, PI3K‐Akt, and MAPK, for improved immunotherapy. Therefore, this NIR‐II light‐mediated optogenetic system provides a promising method for the controlled in situ release of important cytokines in the 3D tumor immune microenvironment for immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing National Laboratory for Molecular Sciences, Key Laboratory of Organic Solids, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
- College of Chemistry, University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
ORCID-Profile: Shu Wang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Lin, H., Cheng, J., Li, R., Zhu, C., Zhao, Y., Yang, Z., Song, G., Huang, Y., Lv, F., Bai, H., & Wang, S. (2026). A New Strategy for Controlled In Situ Release of IL‐2 from Tumor Spheroids Using a NIR‐II Light‐Mediated Optogenetic Manipulation System. Advanced Materials. https://doi.org/10.1002/adma.202516726
Vancouver
Lin H, Cheng J, Li R, Zhu C, Zhao Y, Yang Z, et al. A New Strategy for Controlled In Situ Release of IL‐2 from Tumor Spheroids Using a NIR‐II Light‐Mediated Optogenetic Manipulation System. Advanced Materials. 2026. doi:10.1002/adma.202516726
BibTeX
@article{Lin2026,
author = {Lin, Hongrui and Cheng, Junjie and Li, Rui and Zhu, Chuanwei and Zhao, Yan and Yang, Zhiwen and Song, Gang and Huang, Yiming and Lv, Fengting and Bai, Haotian and Wang, Shu},
title = {A New Strategy for Controlled In Situ Release of IL‐2 from Tumor Spheroids Using a NIR‐II Light‐Mediated Optogenetic Manipulation System},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202516726}
}
EUVIMED